GlassScriptPhysician profile
Stefanie Brackin
NPI 1225512635
$50,680.75
in general payments reported to CMS, 2019-2025
42 companies · $21.65 in 2025
The $21.65 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26K · 2023: $12K · 2024: $13K · 2025: $21.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,871 · Travel and Lodging: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,011.25 |
| Food and Beverage | $5,871.42 |
| Travel and Lodging | $134.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43,245.08 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $777.91 | 2022-2024 | |
| Emd Serono, INC. | $737.80 | 2022-2024 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $705.86 | 2022-2024 | Ultomiris |
| Sk Life Science, INC. | $679.03 | 2022-2024 | Xcopri |
| Biogen, INC. | $640.87 | 2022-2024 | Vumerity, Tysabri, Spinraza |
| Amgen INC. | $407.33 | 2022 | |
| Mdd US Operations, LLC | $405.31 | 2023-2025 | Apokyn, Gocovri, Gocovri |
| Pfizer INC. | $362.08 | 2023-2024 | |
| Lundbeck LLC | $348.32 | 2022-2024 | Vyepti |
| Lilly USA, LLC | $199.77 | 2022-2024 | Emgality, Reyvow, Kisunla |
| Amneal Pharmaceuticals LLC | $193.07 | 2022-2024 | Rytary |
| Argenx US, INC. | $179.35 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $175.03 | 2022-2024 | Zilbrysq, Briviact |
| Eisai INC. | $170.88 | 2022-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $163.71 | 2022-2024 | Ajovy, Austedo Xr |
| Neurelis, INC. | $144.83 | 2022-2024 | Valtoco |
| Nevro Corp. | $143.89 | 2022-2023 | Senza |
| Neurocrine Biosciences, INC. | $130.64 | 2022-2023 | Ingrezza, Ongentys |
| Sumitomo Pharma America, INC. | $89.76 | 2023 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $80.83 | 2023 | Rexulti |
| Avion Pharmaceuticals | $73.57 | 2022-2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $69.60 | 2022-2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $65.41 | 2022-2023 | Onpattro |
| Biohaven Pharmaceutical Holding Company LTD. | $52.27 | 2022 | |
| Impel Pharmaceuticals INC. | $48.11 | 2023 | Trudhesa |
| Tanabe Pharma America, INC. | $46.93 | 2022-2024 | |
| Banner Life Sciences, LLC | $42.60 | 2023 | |
| Genzyme Corporation | $42.29 | 2023 | |
| Kyowa Kirin, INC. | $39.24 | 2022-2024 | Nourianz |
| Genentech USA, INC. | $37.24 | 2024 | Ocrevus Zunovo, Ocrevus |
| Supernus Pharmaceuticals, INC. | $22.66 | 2022 | |
| Averitas Pharma INC. | $21.14 | 2023 | Qutenza |
| Medtronic, INC. | $21.06 | 2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $19.76 | 2022 | |
| Acadia Pharmaceuticals INC | $16.29 | 2023 | Nuplazid |
| Celgene Corporation | $16.16 | 2024 | Zeposia |
| Boston Scientific Corporation | $15.86 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.82 | 2022 | |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Onzetra Xsail |
| Livanova USA, INC. | $12.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Corium, LLC | $7.40 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Brackin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.